Veterinary NSAIDs (carprofen, meloxicam, firocoxib, robenacoxib)
Sold as Rimadyl, Metacam, Previcox, Onsior
The best-evidenced treatment for arthritis pain in dogs, and the benchmark every newer drug is measured against. The real limit is not whether they work but whether a given older dog's kidneys, liver, and gut can tolerate them long-term.
Why this grade
This is the most replicated finding in canine osteoarthritis medicine. Multiple independent randomized controlled trials, including trials using objective force-plate outcomes rather than owner impressions, show significant improvement with carprofen and meloxicam where placebo and glucosamine-chondroitin produced none. Systematic reviews consistently rank NSAIDs as the best-supported pharmacological option.
What the trials show
Randomized trials using objective kinetic gait analysis found that measured variables improved significantly with carprofen and meloxicam, while a glucosamine-chondroitin product and placebo produced no significant improvement. That is a direct demonstration that the NSAID effect is more than regression to the mean or owner optimism. Effect sizes are clinically meaningful and appear within days rather than weeks. Comparative trials against newer agents such as bedinvetmab and grapiprant generally show similar pain control, with the differences showing up in the side-effect profile rather than in efficacy.
Harms and cautions
Gastrointestinal ulceration and bleeding, kidney injury, and liver enzyme elevation. Risk rises with age, dehydration, pre-existing kidney disease, and concurrent steroid use. In one randomized comparison, the meloxicam arm recorded 17 adverse events versus 4 in the bedinvetmab arm, 9 of them gastrointestinal. Never combine an NSAID with a corticosteroid or with a second NSAID, and observe a washout when switching between NSAIDs.
Practical detail
- Route
- Oral, usually daily
- Typical course
- Ongoing, often with periodic attempts at the lowest effective dose
- Monitoring
- Baseline bloodwork including kidney and liver values, repeated within 2-4 weeks of starting and then every 3-6 months. Stop and call the vet for vomiting, black stool, appetite loss, or increased drinking.
- Cost
- low
Regulatory status
- United States
- Multiple FDA-approved products for canine osteoarthritis pain and inflammation.
- European Union
- Widely authorized.
- Note
- Human NSAIDs such as ibuprofen, naproxen, and aspirin are a different matter entirely and are dangerous to dogs. Never substitute them.
Questions worth asking your vet
- What were my dog's baseline kidney and liver values, and when do we recheck?
- Can we find the lowest effective dose rather than staying at the starting dose indefinitely?
- Which specific signs should make me stop the drug and call you the same day?
- Are any of my dog's other medications, especially steroids, incompatible with this?
The evidence, one study at a time
Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Veterinary Record, 2003;152(11):323-9.
rct 2003
The trial most worth citing when someone argues that arthritis improvement in dogs is all placebo. The NSAID arms separated from placebo on a force plate, which cannot be swayed by owner expectation.
- Design
- Prospective, randomized, double-blind, placebo-controlled, four-arm
- Dogs analyzed
- 71
- Blinding
- double-blind
- Control
- Placebo, plus carprofen and meloxicam as active arms
- Duration
- 60 days
- Population
- 71 client-owned dogs over 20 kg with chronic stable osteoarthritis of the elbow, stifle, or hip
- Primary outcome
- Objective ground reaction forces on force-plate gait analysis, plus owner and orthopedic surgeon assessments
- Result
- Dogs on meloxicam or carprofen showed significant improvement in ground reaction forces, with meloxicam returning values to normal baseline. The nutraceutical and placebo arms did not improve.
- Funding
- See publication
Pye C, et al. Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis. Journal of Small Animal Practice, 2024.
systematic review 2024
Useful for setting expectations about what non-drug approaches can and cannot replace.
- Design
- Systematic review
- Blinding
- not-applicable
- Result
- Positions NSAIDs as the reference standard against which non-pharmaceutical options are judged, and finds most alternatives substantially less well supported.
A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. 2025.
rct 2025
Efficacy comparable to the newer biologic; the tradeoff is tolerability, not pain relief.
- Design
- Randomized, open-label, parallel-group
- Blinding
- open-label
- Control
- Bedinvetmab (active comparator)
- Duration
- Multi-week
- Population
- Client-owned dogs with osteoarthritis
- Primary outcome
- Canine Orthopaedic Index
- Result
- Meloxicam produced a significant reduction in pain scores from baseline, statistically indistinguishable from bedinvetmab, but with more adverse events (17 versus 4).
- Funding
- See publication